[PDF] Top 20 Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease.
Has 10000 "Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease." found on our website. Below are the top 20 most common "Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease.".
Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease.
... One Use Immunosuppressants and Anti-TNF as Monotherapy or Combination Therapy? Several studies in rheumatic diseases and IBD have shown that a cotreatment with an ... Voir le document complet
6
Brain-gut interactions in inflammatory bowel disease.
... role in the pathogenesis of inflammatory bowel diseases ...HPA) and d) the ...system and e) the intestinal response (including the intestinal barrier, the luminal microbiota ... Voir le document complet
53
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort
... the use of infliximab was launched, Keane et ...cases of TB in patients undergoing anti-TNF ther- ...Most of these cases were severe: 12 patients died and 57% ... Voir le document complet
7
Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease.
... total of 3589 patients with moderate-to-severe UC from two national population-based data- bases (USA and Denmark) were included to compare adverse clinical events in patients who discontinued oral ... Voir le document complet
12
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.
... one of these patients underwent dose de‐escalation (Q4W‐Q8W) and at gestational week 20, another woman needed dose escalation ...ception and three (4%) initiated VDZ treatment after ...one in ... Voir le document complet
10
De-escalation of immunomodulator and biological therapy in inflammatory bowel disease.
... recaptured in the event of a relapse. In a multicentre UK study, reintroduction of thiopurine following a previous treatment regimen with thiopurine—lasting a median duration of 6 ... Voir le document complet
32
Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy
... types and stages of malignancies), and that patients were not only exposed to anti-TNF agents but also to immunomodulator and anticancer therapies, and the follow-up ... Voir le document complet
8
Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients
... Canada Inflammatory Bowel Diseases (IBD) are chronic inflammatory disorders, where epithelial defects drive, at least in part, some of the ...culture of human colon organoids. ... Voir le document complet
14
Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease
... Le caractère prédictif des symptômes oculaires pour l’apparition ou la présence d’une inflammation oculaire spécifique dans cette population n’a pas encore été étudié. Nous avons réalisé une étude commune dans les ... Voir le document complet
49
Ecological Structuring of Temperate Bacteriophages in the Inflammatory Bowel Disease-Affected Gut
... aim of this study was to elucidate the ecological structure of the human gut temperate bacteriophage community and its role in inflammatory bowel disease ...proportion ... Voir le document complet
16
Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation
... epithelium and luminal ...imprint of ELA2A overexpression on intestinal barrier breakdown. In addition to an effect on intestinal barrier integrity, ELA2A hyperactivity also induced changes in ... Voir le document complet
13
Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge
... outcome and an intervention could be due to the effect of additional variables that might be responsible for the observed association: a ...mixing of effects 16 that occurs when a factor [confounder] ... Voir le document complet
8
Anti-TNF and Crohn's Disease: When Should We Stop?
... retrospective and prospective cohort analyses [31, 32], suggesting that a therapeutic strategy that would decrease the number of hospitalisations and/or surgeries in CD might have an important ... Voir le document complet
6
The laminin response in inflammatory Bowel disease: protection or malignancy?
... fibronectin and a-smooth-muscle actin staining (Figure ...LMa1 and LMa5 expression levels, histological grading of colitis was performed on the Swiss-roll comprising the entire colon and ... Voir le document complet
13
Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease.
... RISK OF RELAPSE AFTER TREATMENT WITHDRAWAL IN IBD The risk of relapse after treatment withdrawal is probably a point that has been best ...both in Crohn’s disease (CD) and ... Voir le document complet
6
Intestinal dysbiosis in Inflammatory Bowel Disease associated with primary immunodeficiency.
... IBD in remission were recruited at the Gastroenterology Department of the Saint Antoine Hospital (Paris, France) and provided informed consent (local ethics committee: Comité de Protection des ... Voir le document complet
26
Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson's disease
... expression of alpha-synuclein in both the submucosal and myenteric plexus in C o ’ l o co ol 3 figure ...performed in primary cultures of enteric neurons and using nuclear ... Voir le document complet
4
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.
... psoriasiform and eczematiform skin lesions are a significant side effect of anti-TNF ...therapies. In our experience, they frequently occur in women and patients with a ... Voir le document complet
11
Pyroglutamide-Based P2X7 Receptor Antagonists Targeting Inflammatory Bowel Disease
... models of IBD, this model is one of the most popular for drug screening studies as reviewed by Valatas and colleagues ( Valatas ...journal of pharmacology, 2015 ...ulceration and ... Voir le document complet
77
Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection
... Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection... Abstract.[r] ... Voir le document complet
25
Sujets connexes